Navigation Links
Napo Announces Positive Clinical Data Indicating Crofelemer, Could Effectively Treat Cholera
Date:9/22/2008

SAN FRANCISCO, Sept. 22 /PRNewswire/ -- Napo Pharmaceuticals (LSE: NAPL/NAPU) today announces positive clinical data on the effectiveness of crofelemer from a study for CRO-ID in treating severely ill cholera patients in conjunction with an antibiotic and rehydration therapy.

A double-blind placebo-controlled study was conducted in one hundred (100) patients with confirmed severe cholera. Patients were randomized to placebo or 125 mg crofelemer every 6 hours or 250 mg crofelemer every 6 hours in a 1:2:2 randomization scheme. This single center trial was conducted at the International Centre for Diarrhoeal Disease Research (ICDDR, B) in Dhaka, Bangladesh, popularly known as the "cholera hospital" for the state-of-the-art treatment of cholera patients.

The purpose of the trial was to obtain a therapeutic proof-of-concept in the treatment of cholera, by a reduction in the life-threatening fluid loss characteristic of cholera infection. In addition to receiving crofelemer, all patients received a single oral dose of azithromycin and rehydration therapy. These severely ill cholera patients, even when receiving the antibiotic azithromycin and rehydration therapy (but not crofelemer), averaged approximately 8.5 liters of stool volume output during the first 24 hour period. The primary endpoint in this study was the reduction in stool volume output normalized to the body weight of the cholera patients.

Following the exclusion of three outlier patients, the data demonstrates that a crofelemer dose of 125 mg every 6 hours reduced the amount of stool volume output normalized to body weight by 32% (p=0.028, Mann-Whitney test) in the first 6 hour period (0-6 hours). A 31% reduction in normalized stool volume output was also observed during the first 12 hour period (0-12 hours) with crofelemer 125 mg every 6 hours (p=0.072, Mann-Whitney test). The higher dose of crofelemer (250 mg every 6 hours) also showed a trend towards significance in the first 12
'/>"/>

SOURCE Napo Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Encorium Announces the Initiation of a Strategic Partnership With Prologue Research After the Postponement of Negotiations Regarding Its Planned Acquisition; Strategic Reorganization and Cost Reduction Plan Initiated as Strategic Alternatives are Investig
2. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) Needle
3. Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis
4. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
5. Spherics, Inc. Announces Reduced Cognitive Impairment of Novel Extended Release Topiramate (SRx-502) as Compared to Topamax(R)
6. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
7. Sunshine Heart Announces IDE Approval To Begin C-Pulse U.S. Clinical Feasibility Trial
8. Cerimon Pharmaceuticals Announces Positive Results from a Phase II Clinical Study of Its Diclofenac Sodium Patch for Acute Pain
9. Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
10. Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD
11. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 Five MinuteClinic walk-in medical clinics ... metropolitan area. Three clinics opened in Memphis ... A fourth clinic will be added in Springfield ... Bartlett is expected to open October 22.  MinuteClinic is ... the United States . The ...
(Date:9/19/2014)...  Lpath, Inc. (NASDAQ: LPTN ), ... today that it has entered into definitive agreements ... and 3,605,042 unregistered warrants in a registered direct ... share of common stock and one unregistered warrant ... will be $3.475.  The warrants have an exercise ...
(Date:9/19/2014)... Intarcia Therapeutics, Inc. today announced the presentation ... ITCA 650 (continuous subcutaneous delivery of exenatide) in type ... the 50 th Annual Meeting of the European ... the open-label, phase 3 FREEDOM-HBL (high baseline) trial showed ... poorly controlled type 2 diabetes. The results were presented ...
Breaking Medicine Technology:MinuteClinic Walk-in Medical Clinics Opening in Memphis 2MinuteClinic Walk-in Medical Clinics Opening in Memphis 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
... 26, 2007 - A new study published ... ("A National Survey of,Physician-Industry Relationships") on the ... the need for,profession-wide and public policy reforms ... that the existing,voluntary PhRMA (Pharmaceutical Research and ...
... 2007 - Aeolus,Pharmaceuticals, Inc. (OTCBB:AOLS) announced today ... of the Journal of Neuroscience a study,by ... National Jewish,Medical and Research Center demonstrating that ... 11207, demonstrated,neuroprotection in an animal model of ...
Cached Medicine Technology:Ties Between Physicians and Drug Companies Still Too Strong: the,Prescription Project Offers Solutions to Prevent Conflicts of,Interest 2Study Demonstrating Aeolus Compound's Neuroprotection in,Parkinson's Disease Published in the Journal of Neuroscience 2Study Demonstrating Aeolus Compound's Neuroprotection in,Parkinson's Disease Published in the Journal of Neuroscience 3
(Date:9/21/2014)... September 21, 2014 Market ... (CAS 49562-28-9) Industry, 2009-2019 is a professional ... Chinese Fenofibrate (CAS 49562-28-9) industry. The report ... (CAS 49562-28-9) including its classification, application and ... China’s top manufacturers of Fenofibrate (CAS 49562-28-9) ...
(Date:9/21/2014)... September 21, 2014 “Cluster headaches are ... intense and difficult to resolve,” said Steve Young of ... think of a pain that is more intense.” , ... from cluster headaches, or migraines, that medical research is ... serotonin system,” he added. , Serotonin (5-HT, 5-hydroxytryptamine) is ...
(Date:9/21/2014)... September 21, 2014 According to latest ... highest birth rate since 1966 (10.5 births per 1,000 women ... early 40s has risen steadily by 2 percent per year. ... to women aged 50 and over) also rose, the first ... were more than nine times as many first births to ...
(Date:9/20/2014)... Weight Destroyer , a weight loss ... Wren that has already helped tens of thousands of ... like high blood pressure, high cholesterol, and accelerated aging ... investigative review. , “Weight Destroyer is totally turning ... showing people what is truly effective when it comes ...
(Date:9/20/2014)... Increases in household, construction and commercial ... volumes. However, government regulations and higher landfill disposal ... to IBISWorld industry analyst Alen Allday, “over the ... reducing the volume of waste generated, and increasing ... a large proportion of waste generated by households ...
Breaking Medicine News(10 mins):Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 2Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 3Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 4Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 2Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 3Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 3
... Provider of Affordable Health Insurance Points to President,s Suggestion that ... , AVENTURA, Fla., June 23 Cinergy ... programs for the consumer market, expressed its approval with remarks ... , "As politicians from both sides of the aisle ...
... researchers say , TUESDAY, June 23 (HealthDay News) -- A ... a small study shows. , In the new study, researchers ... (PTMA) system, which is installed via a catheter. , In ... from the left atrium into the left ventricle (from the ...
... need for pacemaker, early death, study shows , TUESDAY, ... an electrocardiogram (EKG), until now thought to be insignificant, ... and an increased risk of early death, a new ... PR interval, the right-hand portion of the jagged blip ...
... are overweight or obese have an increased risk of pancreatic ... with a lower overall survival rate for patients with pancreatic ... of JAMA . Pancreatic cancer is the ... women in the United States. As the prevalence of overweight ...
... ... , ... (PRWEB) June 23, 2009 -- Connextions Inc. today announced the appointment of ... responsibility for management of the company,s 12-member development team at its Technology Center in ...
... ... Chester and Delaware Counties Go Back to School , ... Philadelphia (Vocus) June 23, 2009 -- ... will be awarding scholarships, totaling $82,000, to 41 of its members, on Tuesday, June ...
Cached Medicine News:Health News:Cinergy Health Commentary On President Obama's Call for Cost Control, Competition in Health Insurance Arena 2Health News:New Heart Valve Repair System Tested for Safety 2Health News:Electrocardiogram Blip Signals Heart Trouble 2Health News:Electrocardiogram Blip Signals Heart Trouble 3Health News:Being overweight, obese during early adulthood associated with greater risk of pancreatic cancer 2Health News:Being overweight, obese during early adulthood associated with greater risk of pancreatic cancer 3Health News:Connextions, Inc. Strengthens Technology Capabilities with Addition of Highly Regarded IT Executive 2Health News:Connextions, Inc. Strengthens Technology Capabilities with Addition of Highly Regarded IT Executive 3Health News:41 Keystone Mercy Health Plan Members to Receive Scholarships from the Plan's Employees 2
... The advanced performance benefits of TiMAX™ ... generation of implants. DePuy ACEs Large Fragment ... biocompatibility and enhanced imaging compatibility over traditional ... unique thread design in the TiMAX bone ...
Comprehensive range of integrated implants and instruments including - Basic, Small, Mini, Pelvic and Foot Sets....
Comprehensive range of integrated implants and instruments including - Basic, Small, Mini, Pelvic and Foot Sets....
... Fragment System has been conceived and engineered ... and user-friendly instrumentation. The modular system of ... instrumentation is designed to provide the surgeon ... and classic techniques of open reduction and ...
Medicine Products: